» Articles » PMID: 38470068

European Academy of Neurology (EAN) Guideline on the Management of Amyotrophic Lateral Sclerosis in Collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)

Abstract

Background: This update of the guideline on the management of amyotrophic lateral sclerosis (ALS) was commissioned by the European Academy of Neurology (EAN) and prepared in collaboration with the European Reference Network for Neuromuscular Diseases (ERN EURO-NMD) and the support of the European Network for the Cure ALS (ENCALS) and the European Organization for Professionals and Patients with ALS (EUpALS).

Methods: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the effectiveness of interventions for ALS. Two systematic reviewers from Cochrane Response supported the guideline panel. The working group identified a total of 26 research questions, performed systematic reviews, assessed the quality of the available evidence, and made specific recommendations. Expert consensus statements were provided where insufficient evidence was available.

Results: A guideline mapping effort revealed only one other ALS guideline that used GRADE methodology (a National Institute for Health and Care Excellence [NICE] guideline). The available evidence was scarce for many research questions. Of the 26 research questions evaluated, the NICE recommendations could be adapted for 8 questions. Other recommendations required updates of existing systematic reviews or de novo reviews. Recommendations were made on currently available disease-modifying treatments, multidisciplinary care, nutritional and respiratory support, communication aids, psychological support, treatments for common ALS symptoms (e.g., muscle cramps, spasticity, pseudobulbar affect, thick mucus, sialorrhea, pain), and end-of-life management.

Conclusions: This update of the guideline using GRADE methodology provides a framework for the management of ALS. The treatment landscape is changing rapidly, and further updates will be prepared when additional evidence becomes available.

Citing Articles

Evidence-Based Nutritional Recommendations for Maintaining or Restoring Nutritional Status in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review.

de Carvalho Vilar M, Coutinho K, de Lima Vale S, Dourado Junior M, de Medeiros G, Piuvezam G Nutrients. 2025; 17(5).

PMID: 40077653 PMC: 11901627. DOI: 10.3390/nu17050782.


Percutaneous Endoscopic Gastrostomy in the 21st Century-An Overview of 1415 Consecutive Dysphagic Adult Patients.

Mendes I, Vara-Luiz F, Palma C, Nunes G, Lima M, Oliveira C Nutrients. 2025; 17(5).

PMID: 40077616 PMC: 11902068. DOI: 10.3390/nu17050747.


Neurology and physician-assisted suicide: position of the Italian society of neurology.

Pucci E, Ticozzi N, Comi G, Mancardi G, Provinciali L, Padovani A Neurol Sci. 2025; .

PMID: 40014225 DOI: 10.1007/s10072-025-08038-5.


Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects.

Ruffo P, Traynor B, Conforti F J Neurol. 2025; 272(3):233.

PMID: 40009238 PMC: 11865122. DOI: 10.1007/s00415-025-12975-8.


Neurology and physician-assisted suicide: glossary of definitions and terminology.

Solari A, Ticozzi N, Comi G, Mancardi G, Provinciali L, Padovani A Neurol Sci. 2025; .

PMID: 40009146 DOI: 10.1007/s10072-025-08064-3.


References
1.
Weiss M, Macklin E, McIlduff C, Vucic S, Wainger B, Kiernan M . Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle Nerve. 2020; 63(3):371-383. PMC: 8513796. DOI: 10.1002/mus.27146. View

2.
Miller R, Mitchell J, Moore D . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012; (3):CD001447. PMC: 7055506. DOI: 10.1002/14651858.CD001447.pub3. View

3.
Phukan J, Pender N, Hardiman O . Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007; 6(11):994-1003. DOI: 10.1016/S1474-4422(07)70265-X. View

4.
van Groenestijn A, Schroder C, van Eijk R, Veldink J, Kruitwagen-van Reenen E, Groothuis J . Aerobic Exercise Therapy in Ambulatory Patients With ALS: A Randomized Controlled Trial. Neurorehabil Neural Repair. 2019; 33(2):153-164. DOI: 10.1177/1545968319826051. View

5.
Weiss M, Macklin E, Simmons Z, Knox A, Greenblatt D, Atassi N . A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016; 86(16):1474-81. PMC: 4836879. DOI: 10.1212/WNL.0000000000002507. View